Driven By Purpose
Patients with psychiatric and neurological disorders deserve better treatments. At Xylo, we are developing innovative, mechanism-based therapies to provide effective solutions for these complex conditions. By redefining care, we aim to address critical unmet needs and create lasting impact for patients and healthcare systems.
Our Story
Founded in 2021 in Sydney, we began by pioneering 5-HT receptor based drug discovery, leveraging computational and rational drug design.
In 2024, the company closed a Seed round of financing and flipped up to become a US company. This positions us for the next phase of growth as we expand our pipeline and advance clinical development.
Our goal is to redefine treatments for complex psychiatric and neurological disorders. With a focus on optimized, targeted therapies, we are shaping the next generation of treatments to improve the lives of patients worldwide.
Read more about Psylo’s founding in Cosmos Magazine.
Investors
.webp)